{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T04:06:46Z","timestamp":1754021206939},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"DOI":"10.7759\/cureus.51456","type":"journal-article","created":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T13:14:30Z","timestamp":1704114870000},"source":"Crossref","is-referenced-by-count":2,"title":["Durvalumab-Induced Myocarditis and Dilated Cardiomyopathy in a Patient With Non-small Cell Lung Cancer: A Diagnostic Conundrum"],"prefix":"10.7759","author":[{"given":"Ali","family":"Khreisat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathanial","family":"Bartosek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Amal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavinkumar","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SM, et al.. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60. 10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0782-5","article-title":"Durvalumab: first global approval","volume":"77","author":"Syed YY","year":"2017","unstructured":"Syed YY. Durvalumab: first global approval. Drugs. 2017, 77:1369-76. 10.1007\/s40265-017-0782-5","journal-title":"Drugs"},{"key":"ref3","unstructured":"AstraZeneca Pharmaceuticals LP. Imfinzi (durvalumab) (package Insert). US Food and Drug Administration. (2023). Accessed. December 7, 2023: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761069s042lbl.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1764936","article-title":"Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer","volume":"19","author":"Shibata Y","year":"2020","unstructured":"Shibata Y, Murakami S. Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer. Expert Opin Drug Saf. 2020, 19:653-9. 10.1080\/14740338.2020.1764936","journal-title":"Expert Opin Drug Saf"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.02.003","article-title":"Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: a post-hoc analysis of the PACIFIC trial","volume":"166","author":"Naidoo J","year":"2022","unstructured":"Naidoo J, Vansteenkiste JF, Faivre-Finn C, et al.. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: a post-hoc analysis of the PACIFIC trial. Lung Cancer. 2022, 166:84-93. 10.1016\/j.lungcan.2022.02.003","journal-title":"Lung Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.962596","article-title":"Cardiotoxicity associated with immune checkpoint inhibitors: current status and future challenges","volume":"13","author":"Gan L","year":"2022","unstructured":"Gan L, Liu D, Ma Y, et al.. Cardiotoxicity associated with immune checkpoint inhibitors: current status and future challenges. Front Pharmacol. 2022, 13:962596. 10.3389\/fphar.2022.962596","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood SS","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al.. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018, 71:1755-64. 10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.7644-21","article-title":"Durvalumab-associated late-onset myocarditis successfully treated with corticosteroid therapy","volume":"61","author":"Maetani T","year":"2022","unstructured":"Maetani T, Hamaguchi T, Nishimura T, Marumo S, Fukui M. Durvalumab-associated late-onset myocarditis successfully treated with corticosteroid therapy. Intern Med. 2022, 61:527-31. 10.2169\/internalmedicine.7644-21","journal-title":"Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas N","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020, 9:e013757. 10.1161\/JAHA.119.013757","journal-title":"J Am Heart Assoc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2018.05.014","article-title":"Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: a case report","volume":"25","author":"Mahmood SS","year":"2018","unstructured":"Mahmood SS, Chen CL, Shapnik N, Krishnan U, Singh HS, Makker V. Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: a case report. Gynecol Oncol Rep. 2018, 25:74-7. 10.1016\/j.gore.2018.05.014","journal-title":"Gynecol Oncol Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart","volume":"116","author":"Grabie N","year":"2007","unstructured":"Grabie N, Gotsman I, DaCosta R, et al.. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation. 2007, 116:2062-71. 10.1161\/CIRCULATIONAHA.107.709360","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03101","article-title":"Immune cell composition in human non-small cell lung cancer","volume":"9","author":"Stankovic B","year":"2018","unstructured":"Stankovic B, Bj\u00f8rhovde HA, Skarshaug R, et al.. Immune cell composition in human non-small cell lung cancer. Front Immunol. 2018, 9:3101. 10.3389\/fimmu.2018.03101","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei SC","year":"2021","unstructured":"Wei SC, Meijers WC, Axelrod ML, et al.. A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov. 2021, 11:614-25. 10.1158\/2159-8290.CD-20-0856","journal-title":"Cancer Discov"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/210414-durvalumab-induced-myocarditis-and-dilated-cardiomyopathy-in-a-patient-with-non-small-cell-lung-cancer-a-diagnostic-conundrum","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:13:36Z","timestamp":1707509616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/210414-durvalumab-induced-myocarditis-and-dilated-cardiomyopathy-in-a-patient-with-non-small-cell-lung-cancer-a-diagnostic-conundrum"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.51456","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}